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Abstract
QUESTION UNDER STUDY: Cardiac resynchronisation
therapy (CRT) with defibrillator back-up (CRT-D) is
widely used in selected patients with moderate/severe heart
failure. Renal failure is common in these patients. Data on
the impact of CRT on renal function are controversial and
limited by short follow-up. The aim of this study was to
describe changes in glomerular filtration rate (GFR) from
baseline compared with 1 and 2 years after CRT implanta-
tion.
METHODS: A total of 284 CRT-D patients with creatinine
levels at baseline and after 1 year were identified in two
prospective registries. In 149 patients, levels after 2 years
were available. GFR in ml/min/1.73 m2 was estimated with
the Modification Diet in Renal Disease equation and pa-
tients stratified into GFR stages 1 to 4.
RESULTS: The population was predominantly male
(75%), mean (± standard deviation) age was 61 ± 7 years
and ejection fraction 24% ± 8 %. GFR was 63 ± 24 ml/min/
1.73 m2 at implantation and 60 ± 24 ml/min/1.73 m2 after
1 year (p = 0.26). At the 2-year follow-up, GFR had de-
creased from 60 ± 21 to 56 ± 21 ml/min/1.73 m2 (p = 0.04).
Mean GFR decreased in stages 1 and 2, remained stable
in stage 3 and improved in stage 4 patients. After 2 years,
GFR had decreased ≥10 ml/min/1.73 m2 in 42%, but im-
proved in only 15% (p = 0.04).
CONCLUSIONS: Overall, mean GFR in CRT-D patients
decreases at 1 and 2 years after implantation, depending
in part on the initial degree of renal function. However,
the chance of further substantial deterioration (≥10 ml/min/
1.73 m2) is considerable.
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Introduction
In selected patients with drug refractory heart failure, car-
diac resynchronisation therapy (CRT) without or with a de-
fibrillator (CRT-D) has been shown to reduce both mortal-
ity and morbidity [1–4] and is now a recommended thera-
peutic option for patients with moderate to severe heart
failure and wide QRS complex [5]. Renal failure is a com-
mon co-morbidity in heart failure patients [6–8] and has
also been recognised as an independent risk factor for mor-
bidity and mortality in these patients [9, 10]. Renal failure
is also common in CRT patients [3, 11] where it has been
shown to be an independent predictor of mortality [10].
Decreased cardiac output and venous congestion as meas-
ured by right heart catheterisation have been proposed as
possible pathophysiological mechanisms [12]. Advancing
renal failure has been shown to be associated with a widen-
ing of the QRS complex [6]. As CRT reduces forward fail-
ure and improves cardiac output, it might also lead to an
improvement in renal function. Current data are controver-
sial and limited by a short follow-up [11, 13]. Therefore,
the aims of this study were: a) to determine changes in ren-
al function over a period of at least one year after implant-
ation, if possible after two years and b) to assess this in dif-
ferent stages of renal failure.
Methods
The patients of the present study stemmed from the pro-
spective ICD registries of the Cardiology departments of
the University of Basel Hospital, Switzerland and of
Erasmus MC in Rotterdam, the Netherlands. The registry
in Basel was started on the 1st of July 1999 and covers
a large part of North-Western Switzerland. The registry in
Rotterdam was started on the 1st of October 1998 and cov-
ers a large area around Rotterdam. They encompassed per
end of September 2009, 777 and 1574 patients respectively.
Out of these registries, all patients in whom a CRT-D was
implanted were identified. Patients were included in the
study if serum creatinine levels at baseline and at least after
one year were available. We excluded 18 patients who had
no creatinine level available at baseline and/or after 1 year
(13 and 5 patients). In a subset of patients, creatinine levels
after 2 years of follow-up were also available. The CRT-D
was implanted according to local practice in the two centres
with conscious sedation and mostly dual-coil/passive ICD
leads in Basel and single-coil/active ICD leads in Rotter-
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dam. All clinical diagnosis (e.g., coronary artery disease or
diabetes) were taken from the patient chart.
GFR was estimated via an internet based calculator [14] us-
ing the abbreviated Modification of Diet in Renal Disease
(MDRD) equation [15]. This model was used for its simpli-
city and wide availability, even though it might overestim-
ate renal function [16]. The creatinine levels used for calcu-
lation were always the last ones determined before CRT-D
implantation (usually the day before) and never taken after
the procedure, as contrast agents used for coronary sinus
venography may have an immediate impact on renal func-
tion. Patients were then stratified into one of 4 GFR stages
[17]: Chronic kidney disease (CKD) stage 1 with a normal
kidney function (i.e., a GFR ≥90 ml/min/1.73 m2); CKD
stage 2 with a mild decrease in kidney function (i.e., a GFR
from 60–89 ml/min/1.73 m2); CKD stage 3 with a moder-
ate decrease in kidney function (i.e., a GFR from 30–59 ml/
min/1.73 m2) and CKD stage 4 with a severe decrease in
kidney function (i.e., a GFR <30 ml/min/1.73 m2). In or-
der to differentiate between clinically important changes in
GFR and mere incidental changes in stages (i.e., a decrease
from 61 to 59 ml/min/1.73 m2 is a change in stage based
on the definition, but obviously not clinically relevant), we
empirically defined a change of ≥ ± 10 ml/min/1.73 m2
as “relevant” and determined these changes as well. Mul-
tivariate analyses were performed to determine predictors
for a “relevant” improvement or impairment of GFR as
defined above. Creatinine levels used for the follow-up de-
termination of GFR were those closest to the time point one
and two years after CRT implantation.
Statistics
Continuous data are expressed as mean values (± one
standard deviation [SD]). The chi-square test or Fisher’s
test were used to compare categorical data. Comparisons of
all continuous variables were calculated using an unpaired
two-sided student’s t-test. Univariate and multivariate ana-
lysis with logistic regression were used to examine the
association between baseline clinical characteristics and
changes in GFR during follow-up. Characteristics entered
in the multivariate analysis included NYHA class, LV-ejec-
tion fraction, QRS width, hypertension, diabetes, diurectics
use, ACE/ARB use and CKD stage 3 or 4. Analyses were
done using SPSS version 16.
Results
The study cohort consisted of 284 patients (165 from Rot-
terdam, 119 from Basel). The population was predomin-
antly male (75%) with a mean age of 61 years (SD 7; range
12–82). Ischaemic and non-ischaemic cardiomyopathy
were almost equally distributed, mean LVEF was 24 % (SD
8). Heart failure drug therapy was on an optimal level with
virtually all patients taking ACE-inhibitors or angiotensin
receptor antagonists. The CRT-D was implanted for
primary prevention in 76% of cases. Baseline characterist-
ics are shown in table 1.
GFR values were available in all 284 patients at baseline
and after 1 year of follow-up, and in 149 (52%) patients
after 2 years of follow-up. GFR at baseline was 62.8 ± 24.3
ml/min/1.73 m2 and 60.3 ± 23.6 ml/min/1.73 m2 after one
year (p = 0.26). In the 149 patients with 2 years of follow-
up GFR decreased from 59.7 ± 21.4 ml/min/1.73 m2 to
55.5±21.5 ml/min/1.73 m2 (p = 0.004).
At baseline, moderate to severe impairment in renal func-
tion (i.e. CKD stage 3 or 4) was present in 50% (143/284)
of the patients. This percentage had not changed after 1
year (150/284; 52.8%) or after 2 years (83/149; 55.7%).
Table 1: Baseline characteristics of the 284 patients.
Overall cohort Basel cohort Rotterdam cohort p-value
Age 61 years (SD 7) 63 years (SD 10) 59 years (SD 12) 0.005
Male gender 214 (75%) 101 (85%) 113 (68%) 0.002
ICD indication
Primary prevention 215 (76%) 88 (74%) 127 (77%) 0.58
Ischaemic cardiomyopathy 131 (46%) 51 (43%) 80 (48%) 0.40
With CABG * 67 (51%) 27 (53%) 42 (52%) 1.00
Ejection fraction (n = 254) 24% (SD 8%) 24% (SD 7%) 24% (SD 7%) 0.63
NYHA class 2.75 (SD 0.49) 2.76 (SD 0.53) 2.73 (SD 0.46) 0.60
II 79 (28%) 34 (29%) 45 (27%)
III 198 (70%) 79 (66%) 119 (72%)
IV 7 (2%) 6 (5%) 1 (1%)
Sinus rhythm 207 (73%) 106 (89%) 101 (61%) 0.0001
Hypertension 119 (42%) 73 (61%) 46 (28%) 0.0001
Diabetes 77 (27%) 30 (25%) 47 (28%) 0.6
QRS width 164 ms (SD 27 ms) 161 ms (SD 31 ms) 167 ms (SD 30 ms) 0.14
Drug therapy at inclusion
ACE inhibitors/ARBs 273 (96%) 115 (97% 158 (96%) 0.77
Diuretics 249 (88%) 109 (92%) 140 (85%) 0.1
Beta-blockers 222 (78%) 96 (81%) 126 (76%) 0.47
Amiodarone 74 (26%) 33 (28%) 40 (24%) 0.58
CKD † stage 1 46 (16%) 21 (18%) 25 (15%)
CKD stage 2 95 (33%) 38 (32%) 57 (34%)
CKD stage 3 124 (44%) 52 (44%) 72 (44%)
CKD stage 4 19 (7%) 8 (7%) 11 (7%)
* Coronary artery bypass graft; † Chronic kidney disease
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Mean GFR of patients in CKD stages 1 and 2 (i.e., those
with a normal or near-normal renal function) decreased, re-
mained stable in stage 3 and improved in stage 4, especially
after a follow-up of 2 years (for details see table 2).
Changes in GFR of ≥10 ml/min/1.73 m2 were observed
in 134/284 patients after 1 year (decrease in GFR of ≥10
ml/min/1.73 m2 in 30%, increase of ≥10 ml/min/1.73 m2
in 17%, p-p-valuevalue 0.19). After 2 years, GFR had de-
creased for ≥10 ml/min/1.73 m2 in 42%, and improved in
only 15% (p-value 0.04). Patients in CKD stages 3 and 4
increased their GFR for >10 ml/min/1.73 m2 more often
than those in stage 1 and 2 (p value 0.0001 after 1 and 2
years). However, because in CKD stages 3 and 4 a similar
rate of patients (20%–25%) exhibited an increase or a fur-
ther decrease of ≥10 ml/min/1.73 m2, respectively, the ef-
fect of CRT on renal function based on baseline GFR and/
or CKD stage is not predictable. Details of changes in the
different stages are shown in table 3.
During follow-up of 45 ± 9 months, 68 patients (24%) died.
There were differences in GFR both at baseline and after 1
and 2 years of follow-up between survivors and nonsurviv-
ors (56 ± 24 ml/min/1.73 m2 in dead vs 65 ± 24 ml/min/
1.73 m2 in surviving patients at baseline; 53 ± 24 ml/min/
1.73 m2 vs 62 ± 23 ml/min/1.73 m2 after 1 year; 43 ± 21
ml/min/1.73 m2 vs 59 ± 20 ml/min/1.73 m2 after 2 years
(p-values 0.008, 0.005 and 0.0001)). Mortality was 17% in
CKD stage 1, 15% in stage 2, 31% in stage 3 and 42% in
stage 4 (p-value 0.007), and 16% in GFR >60 ml/min/1.73
m2 or 32% in GFR <60 ml/min/1.73 m2. Mortality was sim-
ilar in patients with a decrease in GFR of >10 ml/min/1.73
m2 as compared to patients with improved or stable GFR
(29.4% vs 25.0% vs 20.5%). ICD therapies were delivered
in 107 patients (38%). There was no association between
ICD therapy and the different CKD stages (p-value 0.35).
In the univariate analysis, only age (OR per year 0.977
[CI 0.957–0.997] p-value 0.028) and CKD stage 3 and 4
(OR 0.338 [CI 0.123–0.930] p-value 0.036) were negative
predictors for an improvement of GFR >10 ml/min/1.73
m2 after 1 year. In the multivariate analysis only baseline
CKD stage 3 and 4 (OR 0.339 [CI 0.123–0.933] p-value
0.036) remained in the model. Considering an impairment
of GFR > 10 ml/min/1.73 m2 after 1 year, QRS width was
the only significant covariate in univariate analysis (OR per
ms 0.990 [CI 0.983-0.997] p-value 0.005).
In a separate analysis we compared the 77 patients (27%)
with diabetes to the 207 nondiabetic patients. Both at im-
plantation and after 1 year of follow-up, diabetic patients
were in a higher CKD stage (p-values 0.009 and 0.05, re-
spectively) and had lower mean GFR values, but exhibited
a similar decline in GFR (tables 4 and 5). The same shifts in
GFR as in nondiabetics were seen according to CKD stages
(1 – 10 ml, 2 – 8 ml, 3 – 1 ml, 4+ 10 ml). Due to the small
number (n = 38), no analysis was performed after 2 years.
Table 2: Changes of mean glomerular filtration rate (GFR) according to baseline CKD stage after 1 and 2 years.
n Baseline GFR GFR after 1 year p-value
Overall 284 62.8 ± 24.3 60.3 ± 23.6 0.26
Baseline CKD † stage 1 46 (16%) 101.9 ± 13.8 87.5 ± 23.2 0.0005
Baseline CKD stage 2 95 (33%) 73.0 ± 8.0 69.6 ± 14.6 0.04
Baseline CKD stage 1+2 141 (50%) 82.5 ± 17.0 75.5 ± 19.7 0.002
Baseline CKD stage 3 124 (44%) 46.6 ± 7.9 47.4 ± 15.8 0.62
Baseline CKD stage 4 19 (7%) 22.5 ± 5.0 31.8 ± 14.0 0.01
Baseline CKD stage 3+4 143 (50%) 43.4 ± 11.1 45.3 ± 16.4 0.25
Baseline GFR GFR after 2 years p-value
Overall 149 59.7 ± 21.4 55.5 ± 21.4 0.04
Baseline CKD stage 1 24 (16%) 99.5 ± 9.8 74.6 ± 20.1 0.0001
Baseline CKD stage 2 50 (33%) 73.6 ± 8.3 62.3 ± 19.2 0.0002
Baseline CKD stage 1+2 74 (50%) 82.0 ± 15.0 66.3 ± 20.3 0.0001
Baseline CKD stage 3 65 (44%) 47.4 ± 7.5 47.3 ± 16.6 1
Baseline CKD stage 4 10 (7%) 24.1 ± 4.3 29.6 ± 9.4 0.1
Baseline CKD stage 3+4 75 (50%) 44.3 ± 10.8 45.0 ± 17.0 0.78
† Chronic kidney disease
Table 3: Changes in glomerular filtration rate according to baseline CKD stage after 1 and 2 years.
n Increase in GFR ≥10 Decrease in GFR ≥10
After 1 year:
Overall 284 49 (17%) 85 (30%)
Baseline CKD † stage 1 46 3 (7%) 28 (61%)
Baseline CKD stage 2 95 14 (15%) 31 (33%)
Baseline CKD stage 3 124 25 (20%) 26 (21%)
Baseline CKD stage 4 19 7 (37%) 0 (0%)
After 2 years:
Overall 149 22 (15%) 63 (42%)
Baseline CKD stage 1 24 0 (0%) 21 (87%)
Baseline CKD stage 2 50 4 (8%) 24 (48%)
Baseline CKD stage 3 65 15 (23%) 18 (28%)
Baseline CKD stage 4 10 3 (30%) 0 (0%)
† Chronic kidney disease
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Discussion
Main findings of this study
At implantation, 50% of CRT patients had a moderate to
severe reduction in renal function. After 2 years, mean
GFR declined further. An impaired renal function conveys
a worse prognosis. While patients with a normal or mildly
reduced GFR exhibited a significant decrease in GFR dur-
ing mid-term follow-up, patients with severely impaired
GFR improved, but their mean GFR was still <30 ml/min/
1.73 m2.
In a contemporary heart failure population, 40%–50% of
patients present with a GFR of <60 ml, regardless of
whether they are seen in an outpatient setting [6], or wheth-
er they are implanted with an ICD [17] or a CRT-D [3, 10,
18, 19]. 5%–8% of patients had a GFR of <30 ml ml/min/
1.73 m2, often heading towards haemodialysis. In this set-
ting, it is important to know if CRT can affect this course as
it was shown that an ICD offers no benefit in patients with
severely impaired renal function [20].
Evolution of GFR over time
Current literature related to the evolution of GFR in CRT
patients is small and limited by a short follow-up period of
3 to 6 months [11, 13, 19, 21], methodological problems
[14], a main focus on mortality [22] or a vague definition of
CKD stages [20, 21]. In the present study, all 284 patients
had GFR estimations at 1 year follow-up and also almost
50% after 2 years. By combining the literature on short-
term follow-up [11, 18, 21, 22] with our data, we tried to
speculate on the evolution of GFR over a period of 2 years.
Mean GFR decreases slightly (0–2 ml) after 3 to 6 months
and this decrease continues after one and two years (–2.5
ml and –4 ml). However, there are major differences ac-
cording to baseline renal function. In patients with baseline
GFR >60 ml/min/1.73 m2, GFR decreases between 2 and
10 ml/min/1.73 m2 after 3 to 6 months and the decrease
continues further (–7 ml and ‒16 ml, respectively). In pa-
tients with baseline GFR <60 ml/min/1.73 m2, the opposite
effect is seen. GFR initially improves by 1–8 ml/min/1.73
m2, but goes back to baseline after 1 and 2 years. In patients
with GFR <30 ml/min/1.73 m2, the initial improvement of
3–8 ml/min/1.73 m2 is preserved after 1 and 2 years.
CKD stages are somehow arbitrary. We therefore intro-
duced an empirically chosen level of “change of ±10 ml/
min/1.73 m2” to overcome this. Our analysis demonstrated
that the higher the initial CKD stages were, the more pa-
tients showed an increase of >10 ml/min/1.73 m2 of GFR
after 1 and 2 years and the other way round. There was
a continuous rise of this percentage up to 37% in CKD
stage 4. This could be used as a strong argument in favour
of CRT use even in patients with poor renal function.
However, changes seem unpredictable. The analysis based
on individual patient’s GFR demonstrates that a similar rate
(20%–25%) show a substantial change in either direction.
Thus, a recommendation cannot be given to implant a CRT-
D in a patient with advanced renal failure in hope for sub-
stantial improvement of GFR nor to withhold it applying
the argument that renal function will further decrease and
the patient not draw benefit from the device. However, due
to the competing risk of severe renal failure [20], use of
a CRT-pacemaker instead of a CRT-defibrillator should be
discussed with such patients, as here the main goal in them
might be the reduction in morbidity (primarily less hospit-
alisations for heart failure) and not a reduction in mortality.
Response to CRT
As no standardised follow-up programme including serial
echocardiography was performed, we cannot correlate “re-
sponse” and GFR changes, which is a limitation of this
study. Data on such a correlation are scarce. In a small
study (85 patients, follow-up 3 months), patients who “re-
sponded” (i.e. a reduction of 10% in end-systolic volume
of the left ventricle (LVESV)) had a rise of GFR of mean
2 ml, whereas GFR dropped a mean of 13ml in “non-re-
sponders” [13]. A less pronounced difference was seen in
a subgroup of 133 patients published by van Bommel et al.
[21]. “Response” was defined as a reduction in LVESV of
>15%. After 6 months, GFR remained stable in “respon-
ders” (–0.6 ml), whereas it dropped in “nonresponders”
(–4.7 ml, p <0.05). The major limitation of both studies
is their very short follow-up, and no other long-term data
have been presented so far.
Explanations for the findings of this study and
limitations
It seems that in patients with advanced renal failure, some
improve GFR due to better organ perfusion, whereas in
others the damage is already fixed (i.e., significant inter-
stitial fibrosis, tubular atrophy and glomerulosclerosis) and
even with better perfusion no improvement is possible.
Table 4: Absolute values of glomerular filtration rate (GFR) in diabetic (n = 77) vs nondiabetic (n = 207) patients after 1 and 2 years; changes of GFR after 1 year in
diabetics according to baseline CKD stage.
Diabetic Nondiabetic p-value
GFR baseline 58 ± 25 65 ± 24 0.05
GFR at 1 year 55 ± 24 62 ± 23 0.04
GFR at 2 years 49 ± 21 58 ± 21 0.04
Table 5: p-values in diabetic patients 0.5 between baseline and 1 year, 0.06 between baseline and 2 years; in nondiabetic patients 0.3 between baseline and 1 year, 0.01
between baseline and 2 years.
n At baseline After 1 year p-value
Baseline CKD † stage 1 12 99.8 ± 8.6 89.6 ± 17.2 0.08
Baseline CKD stage 2 19 72.9 ± 7.7 65.0 ± 16.4 0.06
Baseline CKD stage 3 35 46.7 ± 8.5 45.6 ± 15.8 0.7
Baseline CKD stage 4 11 22.9 ± 5.0 33.4 ± 16.6 0.06
† Chronic kidney disease
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However, this explanation has the above-mentioned limit-
ation: that we have no data on individual “response”. The
decrease in kidney function within 2 years in CKD stage 1
and 2 patients might not be a sign of ongoing structural kid-
ney damage but be the result of a lower glomerular filtra-
tion pressure by rigorous antihypertensive treatment (e.g.,
ACE inhibitors, angiotensin receptor antagonists). Unfor-
tunately we have no information about whether dosages of
ACE inhibitors, angiotensin receptor antagonists or diuret-
ics were increased in these patients in particular. This is an-
other limitation of the study. In addition, no contemporary
data are available in the literature of a similar patient group
without CRT. Thus it might be that patients without CRT
experience a much larger change in renal function and that
CRT at least prevents severe impairment.
Conclusions
Half of CRT patients have impaired renal function at im-
plantation. Overall, mean GFR decreases significantly after
1 and 2 years. Changes are dependent on baseline CKD
stage. While patients with normal GFR at baseline show a
decrease in GFR, those with very poor GFR experience a
considerable improvement over time. However, evolution
of GFR on an individual basis cannot be predicted, mean-
ing that poor renal function alone should not be used as an
argument against CRT. Further research is necessary, with
an even longer follow-up period and a special focus on dif-
ferent definitions of response and its impact on renal func-
tion.
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